1
CER‑T therapy shows initial safety signals and prompts protocol expansion
CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric engulfment receptor T‑cell therapy being tested in patients with acute myeloid leukaemia.
Investigators have completed the dose‑limiting toxicity observation period in the first cohort and reported cell expansion with no cytokine release syndrome, no ICANS and no treatment‑related adverse events so far, marking a positive early safety indication for an engineered T‑cell approach in…